Merck has answered Bloomberg reporter Shannon Pettypiece's questions about this meta-analysis study I detailed last night, which is reprinted in the Chicago Daily Herald, thus:
. . . ."Throughout their article, the authors cite numerous limitations of their meta-analysis," Merck said in the statement. Researchers "did conclude that statin-ezetimibe combinations are more likely to result in attainment of goals" set by U.S. guidelines, according to the e-mail.
"In terms of clinical outcomes, we believe randomized, well-controlled clinical trials are the gold standard for assessing clinical outcomes," Merck said. . . .
So, I guess Schering-Plough and Merck would prefer that we just sit tight -- until 2013 -- for IMPROVE-IT results. Gee, that's less than 1,590 days away now (see left margin counter). Sure. I'll just sit tight, on that, while all the evidence piles up, the other way. Or. Not.
No comments:
Post a Comment